Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

Novartis Vaccines63 enrolled

Overview

The present study is designed to confirm the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant, formulation 2013/2014 Northern Hemisphere, in adults ≥65 years of age. For the immunogenicity endpoints the antibody response to each influenza vaccine antigen, will be measured by means of Single Radial Hemolysis (SRH) or Hemagglutination Inhibition (HI) at approximately 21 days post immunization. The vaccine composition will be based on the World Health Organization (WHO) recommended influenza strains for 2013/2014 Northern Hemisphere. The results of this study are intended to support the use of this vaccine in future influenza seasons if the recommended vaccine composition remains the same, in compliance with the requirements of the current European Union (EU) recommendations for clinical trials related to yearly licensing of influenza vaccines.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Human Influenza

Interventions

Eligibility

Sex: ALLMin age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female volunteers aged 65 years or older, mentally competent, who gave written informed consent prior to study entry; * Were able to comply with all the study requirements; and * Were in good health as determined by the outcome of medical history, physical examination, and clinical judgment of the investigator. Exclusion Criteria: * Had behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may have interfered with the subject's ability to participate in the study; * Had a serious chronic or acute disease (in the judgment of the investigator) including, but not limited to: * medically significant cancer (except for benign or localized skin cancer, cancer in remission for \>= 10 years, or localized prostate cancer that has been clinically stable for \> 2 years without treatment) * medically significant advanced congestive heart failure (ie, New York Heart Association \[NYHA\] class III and IV) * chronic obstructive pulmonary disease (ie, Global initiative for chronic Obstructive Lung Disease \[GOLD\] stage III and IV) * autoimmune disease (including rheumatoid arthritis and excepting Hashimoto's thyroiditis that has been clinically stable for \>= 5 years) * diabetes mellitus type I * poorly controlled diabetes mellitus type II * advanced arteriosclerotic disease * history of underlying medical condition such as major congenital abnormalities requiring surgery, chronic treatment, or associated with developmental delay (eg, Down's syndrome) * acute or progressive hepatic disease * acute or progressive renal disease * severe neurological (especially Guillain-Barré syndrome) or psychiatric disorder * severe asthma * Had a history of any anaphylactic reaction and/or serious allergic reaction to any component of the study vaccine. * Had a known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting, for example, from: * receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study, * receipt of immunostimulants within the past 6 months, * receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivates within the past 3 months and for the full length of the study, or * suspected or known human immunodeficiency virus (HIV) infection or HIV related disease. * Had known or suspected drug or alcohol abuse within the past 2 years; * Had bleeding diathesis or conditions associated with prolonged bleeding time that, in the investigator's opinion, would have interfered with the safety of the subject; * Was not able to comprehend and to follow all required study procedures for the whole period of the study; * Had a history or any illness that, in the opinion of the investigator, would have posed additional risk to the subjects because of participation in the study; * Had the following within the past 6 months: * any laboratory confirmed seasonal or pandemic influenza disease, * received any seasonal or pandemic influenza vaccine. * Had received any other vaccine within 4 weeks prior to enrollment in this study or who were planning to receive any vaccine during the study; * Had acute or chronic infections requiring antiviral therapy within the last 7 days; * Had experienced fever (ie, body temperature \[preferably oral\] \>= 38.0°C) within the last 3 days of intended study vaccination; * Had been participating in any clinical trial with another investigational product 4 weeks prior to first study visit or intended to participate in another clinical study at any time during the conduct of this study; * Was part of study personnel or had close family members conducting this study; * Had a body mass index (BMI) \>35 kg/m2 (BMI is calculated by dividing the subject's weight in kilograms by the subject's height in meters multiplied by the subject's height in meters)

Outcomes

Primary Outcomes

Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV

Immunogenicity was assessed in terms of percentages of adult subjects ≥65 years of age with SRH areas ≥25mm2 against each of the three vaccine strains, three weeks after receiving one dose of aTIV. The related European Committee for Human Medicinal Products (CHMP) criterion for the assessment of immunogenicity is met if the percentage of subjects achieving post vaccination SRH areas ≥ 25mm2 is \>60%.

Time frame: Day 1 (baseline) and Day 22

Percentages of Subjects With Seroconversion or Significant Increase in SRH Area, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV

Immunogenicity was assessed in terms of percentages of adult subjects ≥65 years of age achieving seroconversion or significant increase in SRH area against each of the three vaccine strains, three weeks after receiving one dose of aTIV. Seroconversion is defined as percentage of subjects with a pre-vaccination SRH area ≤4mm2 achieving a post-vaccination SRH area ≥25 mm2. Significant increase is defined as percentage of subjects with a pre-vaccination SRH area \>4mm2 achieving at least 50% increase in post-vaccination SRH area. The related European (CHMP) criterion for the assessment of immunogenicity is met if\>30% of subjects achieve seroconversion or significant increase in post-vaccination SRH area.

Time frame: Day 22

Geometric Mean Ratio (GMR) of Post Vaccination Versus Pre Vaccination Geometric Mean Areas (GMAs), Against Each of Three Vaccine Strains After Receiving One Dose of aTIV

The antibody responses following one dose of aTIV were evaluated in terms of geometric mean ratio GMRs of post vaccination GMAs to pre vaccination GMAs against each of the three vaccine strains, three weeks after receiving one dose of aTIV. The related European (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is \> 2.0.

Time frame: Day 22/Day 1

Percentages of Subjects With Haemagglutinin Inhibition(HI) Titers ≥40, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV.

Immunogenicity was assessed in terms of percentages of adult subjects ≥65 years of age with HI titers ≥40, against each of the three vaccine strains, three weeks after receiving one dose of aTIV. The related European (CHMP) criterion for the assessment of immunogenicity is met if the of subjects achieving HI titers ≥ 40 is \>60%.

Time frame: Day 1 (baseline) and Day 22

Percentages of Subjects With Seroconversion or Significant Increase in HI Antibody Titers, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV

Immunogenicity was assessed in terms of percentages of adult subjects ≥65 years of age achieving seroconversion or significant increase in HI antibody titers after receiving one dose of aTIV. Seroconversion is defined as percentage of subjects with a pre-vaccination HI titer \<10 to a post-vaccination titer ≥40. Significant increase is defined as percentage of subjects with a pre-vaccination HI titer ≥10 to at least a 4-fold increase in post-vaccination HI antibody titers. The related European (CHMP) criterion for the assessment of immunogenicity is met if \>30% of subjects achieve seroconversion or significant increase in post-vaccination HI titers.

Time frame: Day 22

Geometric Mean Ratio (GMR) of Post Vaccination Versus Pre Vaccination HI Titers, Against Each of Three Vaccine Strains After Receiving One Dose of aTIV

The antibody responses following one dose of aTIV were evaluated in terms of GMRs of post vaccination geometric mean HI titers against each of the three vaccine strains, three weeks after receiving one dose of aTIV. The related European (CHMP) criterion for the assessment of immunogenicity is met if the GMR day 22/day 1 is \> 2.0.

Time frame: Day 22/Day 1

Number of Subjects Reporting Solicited Adverse Events After Receiving One Dose of aTIV

The number of adult subjects ≥65 years of age reporting solicited local and systemic adverse events and other solicited adverse events after receiving one dose of aTIV are reported.

Time frame: Day 1 to Day 4 post vaccination

Number of Subjects Reporting Unsolicited Adverse Events After Receiving One Dose of aTIV

The number of adult subjects ≥65 years of age subjects reporting any unsolicited adverse event (AEs) between Day 1 to 4 and serious adverse events (SAEs), medically attended AEs, AEs leading to withdrawal from the study between Day 1 to Day 22 after receiving one dose of aTIV are reported.

Time frame: Day 1 to Day 22 post-vaccination